Galera Therapeutics, Inc. (GRTX)

NASDAQ: GRTX · IEX Real-Time Price · USD
2.64
-0.24 (-8.33%)
At close: Jan 21, 2022 4:00 PM
2.58
-0.06 (-2.27%)
After-hours:Jan 21, 2022 7:55 PM EST
Market Cap69.80M
Revenue (ttm)n/a
Net Income (ttm)-83.79M
Shares Out26.44M
EPS (ttm)-3.30
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume606,031
Open2.83
Previous Close2.88
Day's Range2.58 - 2.89
52-Week Range1.19 - 12.99
Beta1.98
AnalystsBuy
Price Target15.50 (+487.1%)
Earnings Daten/a

About GRTX

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with ...

IndustryBiotechnology
IPO DateNov 7, 2019
Employees38
Stock ExchangeNASDAQ
Ticker SymbolGRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for GRTX stock is "Buy." The 12-month stock price forecast is 15.50, which is an increase of 487.12% from the latest price.

Price Target
$15.50
(487.12% upside)
Analyst Consensus: Buy

News

Galera to Present at H.C. Wainwright BioConnect Conference

MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

2 weeks ago - GlobeNewsWire

Top Penny Stocks to Buy in 2022? Check These 3 Out Right Now

Which penny stocks are you buying right now? The post Top Penny Stocks to Buy in 2022?

Other symbols:KOSRIG
3 weeks ago - PennyStocks

Trending Penny Stocks to Buy Today? 3 For Your Watchlist

Which penny stocks are you watching right now? The post Trending Penny Stocks to Buy Today?

Other symbols:JAGXPTPI
1 month ago - PennyStocks

Galera Therapeutics Shares Surge As Citi Bumps Up Price Target To $20

Citi has raised the price target on Galera Therapeutics Inc (NASDAQ:GRTX) to $20 (suggesting 361% upside) from $11 and maintained a Buy rating.  Analyst Yigal Nochomovitz is re-introducing avasopasem wi...

1 month ago - Benzinga

Check These Penny Stocks Out For Your Watchlist As the Market Dips

Which penny stocks are you watching as 2021 comes to an end? The post Check These Penny Stocks Out For Your Watchlist As the Market Dips appeared first on Penny Stocks to Buy, Picks, News and Informatio...

Other symbols:BBIGFSM
1 month ago - PennyStocks

Are Options Traders Betting on a Big Move in Galera (GRTX) Stock?

Investors need to pay close attention to Galera (GRTX) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Penny Stocks Are Volatile, Here's How to Trade Them and 3 to Watch

Wondering how to trade penny stocks and which could be worth watching? The post Penny Stocks Are Volatile, Here's How to Trade Them and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and ...

Other symbols:CPSHCSCW
1 month ago - PennyStocks

GRTX Stock Alert: The Surprising News That Has Galera Therapeutics Going Gangbusters Today

Galera Therapeutics (GRTX) stock is rocketing higher on Tuesday after the company revealed corrected results from a Phase 3 clinical trial. The post GRTX Stock Alert: The Surprising News That Has Galera...

1 month ago - InvestorPlace

Why Galera Shares Are Surging More Than Double Today?

Galera Therapeutics Inc (NASDAQ: GRTX) has announced corrected results from its Phase 3 ROMAN trial of avasopasem for RT-induced severe oral mucositis (SOM) in patients with locally advanced head and ne...

1 month ago - Benzinga

Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Tr...

Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045)

1 month ago - GlobeNewsWire

Galera to Present at Two Upcoming Investor Conferences in November

MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

2 months ago - GlobeNewsWire

Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis

2 months ago - GlobeNewsWire

Galera Therapeutics, Inc. (GRTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Galera Therapeutics, Inc. (GRTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...

2 months ago - Zacks Investment Research

All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy

Galera Therapeutics, Inc. (GRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago - Zacks Investment Research

Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal

Galera's (GRTX) phase III ROMAN study on avasopasem for treating radiotherapy-induced severe oral mucositis in patients with head and neck cancer fails to meet its primary endpoint. Shares fall.

3 months ago - Zacks Investment Research

Galera Therapeutics plummeted 73% on Tuesday: explore why

Shares of Galera Therapeutics Inc (NASDAQ: GRTX) tanked 73% on Tuesday after the company said its Avasopasem trial did not meet the primary endpoint. Avasopasem does not ‘significantly' reduce the incid...

3 months ago - Invezz

Why Did Galera Therapeutics Shares Plunge To All Time Lows Today?

Galera Therapeutics Inc (NASDAQ: GRTX) stock has plunged to all-time since its listing in November 2019 in reaction to disappointing data from the Phase 3 ROMAN trial of avasopasem manganese in severe o...

3 months ago - Benzinga

Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis

Primary endpoint of reduction in incidence of severe oral mucositis (SOM) not met

3 months ago - GlobeNewsWire

Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance ...

MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

3 months ago - GlobeNewsWire

Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with ...

Event to be webcast on Thursday, September 23 at 11:00 a.m. ET

4 months ago - GlobeNewsWire

Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters

Improvements observed in overall survival, progression-free survival, local tumor control, time to metastases, and tumor response rate

4 months ago - GlobeNewsWire

Galera to Present at Three Upcoming Investor Conferences in September

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr...

4 months ago - GlobeNewsWire

Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments

Completed enrollment in pivotal Phase 3 ROMAN trial for severe oral mucositis (SOM) in patients with head and neck cancer; topline data expected in Q4 2021

5 months ago - GlobeNewsWire

Galera to Present at the Jefferies Virtual Healthcare Conference

MALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprie...

7 months ago - GlobeNewsWire